Stay updated with breaking news from 21835210. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ingalls & Snyder LLC cut its position in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,360,485 shares of the biotechnology company’s stock after selling 9,532 shares during the quarter. Corcept Therapeutics makes up […]
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has received a consensus rating of “Hold” from the seven analysts that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among analysts that […]
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has been assigned a consensus rating of “Hold” from the seven brokerages that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among analysts […]
Corcept Therapeutics (NASDAQ:CORT – Get Free Report)‘s stock had its “hold” rating restated by Truist Financial in a report issued on Monday, Benzinga reports. They currently have a $29.00 price target on the biotechnology company’s stock. Truist Financial’s price target would suggest a potential upside of 9.93% from the stock’s current price. A number of […]
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $32.48, for a total value of $812,000.00. Following the completion of the sale, the insider now owns 73,610 shares in the […]